stockrowVertex Pharmaceuticals Incorporated
VRTX Healthcare Biotechnology
Vertex Pharmaceuticals Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $12.0 billion, up 8.90% from fiscal 2024.
- Revenue
- +11.9%
- EPS
- −39.2%
- Free cash flow
- −52.1%
Quarter to September 2026, against a year earlier
Follow VRTX
Alert me
Vertex Pharmaceuticals Incorporated (VRTX) Return on assets
Vertex Pharmaceuticals Incorporated's return on assets over the twelve months to 30 September 2026 was 13.8%, down 2.6 percentage points from fiscal 2025 (16.4%). Over the past ten years it has ranged from −23.0% (fiscal 2015) to 42.8% (fiscal 2018); the current reading is higher than 55% of that period. That is above the Biotechnology industry median of −46.1% and above the Healthcare sector median of −29.5%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | 16.4% | 18.78 |
| FY2024 | −2.37% | (20.08) |
| FY2023 | 17.7% | (3.33) |
| FY2022 | 21.0% | 2.44 |
| FY2021 | 18.6% | (8.42) |
| FY2020 | 27.0% | 10.86 |
| FY2019 | 16.2% | (26.67) |
| FY2018 | 42.8% | 34.65 |
| FY2017 | 8.18% | 12.33 |
| FY2016 | −4.15% | 18.87 |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| VRTX Vertex Pharmaceuticals Incorporated | 13.8% |
| REGN Regeneron Pharmaceuticals, Inc. compare | 11.4% |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | 10.5% |
| GMAB Genmab A/S Sponsored ADR compare | 8.30% |
| RPRX Royalty Pharma PLC compare | 3.47% |
| ARGX argenex SE compare | 0.00% |
| ROIV Roivant Sciences Ltd. compare | −5.15% |
| MRNA Moderna, Inc. compare | −21.8% |
| RVMD Revolution Medicines, Inc. compare | −57.1% |
| Biotechnology industry median | −46.1% |
| Healthcare sector median | −29.5% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on VRTX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement